Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$1.15 - $1.57 $74,638 - $101,897
-64,903 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$1.4 - $1.9 $28,697 - $38,946
20,498 Added 46.16%
64,903 $104,000
Q1 2021

May 17, 2021

BUY
$1.44 - $2.89 $63,943 - $128,330
44,405 New
44,405 $86,000
Q4 2020

Feb 16, 2021

SELL
$1.39 - $1.87 $34,284 - $46,123
-24,665 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$1.6 - $3.0 $39,464 - $73,995
24,665 New
24,665 $44,000
Q2 2018

Aug 14, 2018

SELL
$3.8 - $8.64 $40,375 - $91,800
-10,625 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$3.7 - $6.09 $39,312 - $64,706
10,625 New
10,625 $62,000

About CALADRIUS BIOSCIENCES, INC.


  • Ticker CLBS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,583,200
  • Market Cap $25.8M
  • Description
  • Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...
More about CLBS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.